<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673786</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P43 3.1</org_study_id>
    <nct_id>NCT04673786</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, active-controlled, double-blind, phase 3 study to compare the&#xD;
      efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque&#xD;
      psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CT-P43, containing the active ingredient ustekinumab, is a human IgG1Îº monoclonal antibody&#xD;
      that is being developed as a biosimilar medicinal product to the reference product, Stelara.&#xD;
      The purpose of this study is to demonstrate similar efficacy and safety of CT-P43 and Stelara&#xD;
      in patients with moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>demonstrate efficacy equivalence</measure>
    <time_frame>from baseline to Week 12</time_frame>
    <description>mean percent improvement in Psoriasis Area and Severity Index (PASI) score of CT-P43 and Stelara. PASI score ranges from 0 to 72. The higher the score, the more severe the disease.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">509</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>CT-P43</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who were initially randomized to the CT-P43 group on Day 1 (Week 0) will continue their treatment with CT-P43 until Week 40.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stelara</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P43</intervention_name>
    <description>45mg or 90mg dose subcutaneous administration</description>
    <arm_group_label>CT-P43</arm_group_label>
    <arm_group_label>Stelara</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stelara</intervention_name>
    <description>45mg or 90mg dose subcutaneous administration</description>
    <arm_group_label>Stelara</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patient has had diagnosis of plaque-type psoriasis for at least 24 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with forms of psoriasis other than plaque-type.&#xD;
&#xD;
          -  Patients previously received ustekinumab or a biosimilar of ustekinumab.&#xD;
&#xD;
          -  Patient who has allergies to the active substance or any of the excipients of&#xD;
             ustekinumab or study drug, or patients with a hypersensitivity to immunoglobulin&#xD;
             products or natural rubber and latex.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Centre</name>
      <address>
        <city>Tartu</city>
        <state>Tartu Country, Estonia</state>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 13, 2020</study_first_submitted>
  <study_first_submitted_qc>December 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

